Hederacoside C

SKU: orb1223311

Description

Mutant EGFR inhibitor is a selective and potent Mutated EGFR inhibitor, inhibits L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant.

Key Properties

• CAS Number: 14216-03-6
• MW: 1221.39
• Purity: >98% (HPLC)
• Formula: C₅₉H₉₆O₂₆
• SMILES: [C@@H]1([C@@H](OC[C@@H]([C@@H]1O)O)O[C@@H]1[C@]([C@H]2[C@@]([C@@H]3[C@]([C@]4(C(=CC3)[C@H]3[C@@](CC4)(CCC(C3)(C)C)C(=O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO[C@H]3[C@@H]([C@H]([C@H](O[C@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)C)O)O)O)[C@H](O3)CO)O)O)O)O)O)C)(CC2)C)(CC1)C)(CO)C)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O
• Target: Histamine Receptor
• Solubility: In Vitro: DMSO : 100 mg/mL (81.87 mM)

Bioactivity

• In Vivo:
  Animal model: TNBS-induced colitis in rat. Dosage: 0.625, 1.25, 2.5 mg/kg. Administration: i.p. Result: Decreased the levels of inflammatory cytokines, including TNF-α, IL-6, IL-1β, CXCL-1, CXCL-2, and CXCL-5.Reduced cell apoptosis in TNBS-induced colitis. Reduced Bax/Bcl-2 ratio, cleaved caspase 3, and p53 protein levels in a dose-dependent manner.
• In Vitro:
  Western blot analysis. Cell line: Caco-2. Concentration: 0.1, 1, 10 μM Incubation time: 1 h. Result: Reduced the expression of p-p65/p65, p-JNK, p-ERK, and p-p38.RT-PCR Cell line: RAW 264.7 Concentration: 5, 10, 50 μg/mL. Incubation time: 1 h. Result: Reduced the expressions of IL-1β, IL-6, TNF-α, and IL-10.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Kalopanaxsaponin B | Hederacoside C | Hederoside H1

Quick Database Links

Gene Symbol

Histamine Receptor